2005 Press ReleasesTo search the press release archives for previous years, please click on the year of interest above before entering your keywords.
 |
| Date | Title | | | Nov.15.05 | Watson Pharmaceuticals to Present at the Credit Suisse First Boston Annual Healthcare Conference| CORONA, Calif., Nov 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Credit Suisse First Boston Annual Healthcare Conference on
Friday, November 18, 2005 at 8:30 a.m. Mountain Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relati... |
|  | | Nov.04.05 | Watson Pharmaceuticals to Present at the CIBC World Markets 16th Annual Healthcare Conference| CORONA, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the CIBC World Markets 16th Annual Healthcare Conference on
Tuesday, November 8, 2005 at 3:00 p.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.... |
| | | Nov.02.05 | Watson Pharmaceuticals Reports Third Quarter 2005 Results|
- Company Reports Total Revenue of $410.3 Million;
Earnings per Share of $0.36 -
- Nine Month Cash Flow From Operations Approaches $280 Million -
CORONA, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its third quarter ended September 30, 2005. Net
revenues increased one percent to $410.3 million, as compared to
$40... |
| | | Oct.18.05 | Watson Pharmaceuticals Named Exclusive Distributor of Authorized Generic OxyContin(R) Tablets| CORONA, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that, under a supply agreement with Purdue Pharma L.P., Watson has been
appointed as the exclusive distributor of authorized generic oxycodone HCl
controlled-release tablets C-II in 10, 20, 40 and 80 mg dosage strengths.
Oxycodone HCl is the generic version of Purdue's OxyContin(R) (C-II) Tablets,
a narcotic analgesic indicated for the ... |
| | | Oct.12.05 | Watson Pharmaceuticals to Host Third Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its third quarter 2005 financial results
on Wednesday, November 2, 2005 after the close of the U.S. financial markets.
The Company will also host a conference call and webcast at 5:00 p.m. Eastern
Standard Time (EST) on Wednesday, November 2, 2005 to discuss the results and
provide an outlook for the ... |
| | | Oct.11.05 | Watson Pharmaceuticals to Consolidate Solid Dosage Manufacturing Facilities| CORONA, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
its plan to consolidate certain of its solid dosage manufacturing operations,
as part of an ongoing effort to optimize the Company's manufacturing
operations.
Over the last several years, Watson has made significant improvements and
enhancements to its solid dosage manufacturing facilities, creating the
opportunity for its Carmel, ... |
| | | Sep.15.05 | Watson Pharmaceuticals Pledges Support for Hurricane Katrina Relief Effort| CORONA, Calif., Sept 15, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it will donate $600,000 worth of brand and generic prescription drug
products and cash to support relief efforts for victims of Hurricane Katrina
in the Gulf States.
In collaboration with a number of major chain drug stores, the Company
will provide access to pharmaceutical products at no cost for pati... |
| | | Sep.13.05 | Watson Pharmaceuticals Announces Completion of $300 Million Share Repurchase Program| CORONA, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that the company has completed its $300 million share repurchase program. The
share repurchase program was announced in February 2005 and authorized the
repurchase of up to $300 million of the company's common stock over a one year
period. Watson has repurchased a total of approximately 9.4 million shares,
or $300 million of its common ... |
| | | Sep.07.05 | Watson Pharmaceuticals to Present at the Bear Stearns 18th Annual Healthcare Conference| CORONA, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Bear Stearns 18th Annual Healthcare Conference on Monday,
September 12, 2005 at 9:00 a.m. Eastern Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watson... |
| | | Aug.08.05 | Watson Pharmaceuticals Dedicates New Distribution Facility in Gurnee, Illinois| GURNEE, Ill., Aug. 8 /PRNewswire/ -- Watson Pharmaceuticals, Inc., a
leading specialty pharmaceutical company, today dedicated a new distribution
facility in Gurnee, Illinois, celebrating the completion of a distribution
operations enhancement initiative. The new 272,000 square-foot facility
nearly doubles Watson's capacity to meet its customers' growing demand for
generic and brand pharmaceutical products.
"We are thrilled to move into our new Gurnee Distribution Center and to
bec... |
| | | Aug.01.05 | Watson Pharmaceuticals Receives FDA Approval for Desogestrel and Ethinyl Estradiol Tablets USP, 0.15MG / 0.03MG| CORONA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that it has received final approval from the United States (U.S.) Food and
Drug Administration (FDA) on its Abbreviated New Drug Application for
desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg, a generic
version of Ortho-McNeil's Ortho-Cept(R) and Organon's Desogen(R) products
which are indicated for the prevention of pregnanc... |
| | | Jul.27.05 | Watson Pharmaceuticals Reports Second Quarter 2005 Results| - Company Reports Total Revenue of $416 Million; Earnings Per Share of $0.35 -
- Six Month Cash Flow From Operations Exceeds $177 Million -
CORONA, Calif., July 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its second quarter ended June 30, 2005. Net revenues
increased 4 percent to $416.3 million, as compared to $399.4 million for the
second quarter ended June 30, ... |
| | | Jul.14.05 | Watson Pharmaceuticals to Host Second Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., July 14 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
(NYSE: WPI), a leading specialty pharmaceutical company, announced today that
the Company intends to release its second quarter 2005 financial results on
Wednesday, July 27, 2005 after the close of the U.S. financial markets. The
Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) on Wednesday, July 27, 2005 to discuss the results and
provide an outlook for the rest of 2005. ... |
| | | Jun.16.05 | Somerset Files Response to EMSAM(R) Action Letter| FDA Considers Response Complete - Issues PDUFA Review Date
PITTSBURGH and CORONA, Calif., June 16 /PRNewswire-FirstCall/ -- Mylan
Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE: WPI),
today announced that Somerset Pharmaceuticals, Inc. has submitted a response
to the United States Food and Drug Administration's Action letter, dated
January 30, 2004, related to EMSAM(R) (selegiline transdermal system). The
FDA has accepted Somerset's May 26, 2005 response as com... |
| | | Jun.13.05 | Watson Pharmaceuticals Commences Phase 3 Studies on Silodosin for Treatment of Benign Prostatic Hyperplasia| CORONA, Calif., June 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced
that it has commenced Phase 3 clinical studies on silodosin, its
investigational drug being studied to treat the signs and symptoms of Benign
Prostatic Hyperplasia (BPH). This condition is characterized by a non-
cancerous enlarged prostate that leads to obstructive and irritative urinary
symptoms. In the United States (US) BPH affects more... |
| | | Jun.10.05 | Watson Pharmaceuticals to Present at the Goldman Sachs 26th Annual Global Healthcare Conference| CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview and update of the
Company's business at the Goldman Sachs 26th Annual Global Healthcare
Conference on Thursday, June 16, 2005 at 11:00 a.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at... |
| | | May.16.05 | Watson Pharmaceuticals to Present at the Banc of America Securities Health Care Conference 2005| CORONA, Calif., May 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Banc of America Securities Health Care Conference on
Wednesday, May 18, 2005 at 1:20 p.m. Pacific Daylight Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at ht... |
| | | May.09.05 | Watson Pharmaceuticals to Webcast Its 2005 Annual Meeting of Stockholders| CORONA, Calif., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company will conduct a live webcast of its 2005 Annual Meeting of
Stockholders on Friday, May 13, 2005 at 9:00 a.m. Pacific Daylight Time.
The live presentation can be accessed at Watson Pharmaceuticals' Investor
Relations Web site at http://ir.watsonpharm.com. An archived version of the
webcast will be availabl... |
| | | May.05.05 | Watson Pharmaceuticals Reports First Quarter 2005 Results|
- Company Reports Total Revenue of $401 Million;
Earnings per Share of $0.33 -
- Cash Flow from Operations Tops $105 Million -
CORONA, Calif., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported
revenue and earnings for its first quarter ended March 31, 2005. Net revenues
declined two percent to $400.8 million, as compared to $409.7 million for t... |
| | | Apr.25.05 | Watson Pharmaceuticals to Host First Quarter 2005 Earnings Conference Call and Webcast| CORONA, Calif., April 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its first quarter 2005 financial results
on Thursday, May 5, 2005 after the close of the U.S. financial markets. The
Company will also host a conference call and webcast at 5:00 p.m. Eastern
Daylight Time (EDT) on Thursday, May 5, 2005 to discuss the results and
provide an outlook for 2005. The dial-in... |
| | | Apr.18.05 | Watson Pharmaceuticals Names Edward F. Heimers, Jr. President of Watson's Brand Division| Industry Veteran to Lead Company's Brand Products Initiatives CORONA, Calif., April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI) today announced the appointment of Edward F. Heimers, Jr.,
58, as Executive Vice President of the company and President of Watson's Brand
division.
"I am very pleased to welcome Ed to the executive management team," began
Allen Chao, Ph.D., Chairman and Chief Executive Officer. "Ed's broad mix of
marketing, sales an... |
| | | Apr.04.05 | Watson Pharmaceuticals' TRELSTAR(R) DEPOT and TRELSTAR(R) LA (Triptorelin Pamoate for Injectable Suspension) Now Available Nationwide| CORONA, Calif., April 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, has made
available nationwide TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate
for injectable suspension) for the palliative treatment of advanced prostate
cancer when orchiectomy (surgical removal of the testicles) or estrogen
administration are either not indicated or are unacceptable to the patient.
TRELSTAR(R), a synthetic hor... |
| | | Mar.28.05 | Watson Pharmaceuticals to Present at the Lehman Brothers Eighth Annual Global Healthcare Conference| CORONA, Calif., March 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the Lehman Brothers 8th Annual Global Healthcare Conference on
Wednesday, March 30, 2005 at 9:00 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://... |
| | | Mar.14.05 | Watson Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Healthcare Conference| CORONA, Calif., March 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview of the Company's
business at the SG Cowen & Co. 25th Annual Healthcare Conference on Thursday,
March 17, 2005 at 10:30 a.m. Eastern Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wats... |
| | | Feb.10.05 | Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Results| - Fourth Quarter Total Net Revenue Reaches $424 Million -
-2004 Total Net Revenue Grows to Over $1.6 Billion -
-Board Authorizes Up To $300 Million Share Repurchase Program -
-Company Provides Outlook for 2005 -
CORONA, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, reported today
its financial results for the fourth quarter and full year ended December 31,
2004. Total... |
| | | Feb.03.05 | Watson Pharmaceuticals to Host Fourth Quarter and Full Year 2004 Earnings Conference Call and Webcast| CORONA, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that the Company intends to release its fourth quarter and full year 2004
financial results on Thursday, February 10, 2005 after the close of the U.S.
financial markets. The Company will also host a conference call and webcast
at 5:00 p.m. Eastern Standard Time (EST) on Thursday, February 10, 2005 to
discuss the results and provide an outlo... |
| | | Jan.07.05 | Watson Pharmaceuticals to Present at the 23rd Annual JPMorgan Healthcare Conference| CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that Watson's senior management will provide an overview and update of the
Company's business at the 23rd Annual JPMorgan Healthcare Conference on
Monday, January 10, 2005 at 4:00 p.m. Pacific Standard Time.
This presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.wa... |
| |
|
|
|
